Literature DB >> 16290001

Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis.

Ching-Chou Tsai1, Yi-Shan Liu, Eng-Yen Huang, Shun-Chen Huang, Hsueh-Wen Chang, Chih-Weng Tseng, Chan-Chao ChangChien.   

Abstract

OBJECTIVE: This investigation attempted to clarify the value of preoperative serum CA125 in predicting histopathological prognostic factors for early-stage cervical adenocarcinoma without lymph node metastasis.
METHODS: This study initially surveyed 163 patients with clinical stage Ib or IIa cervical adenocarcinoma treated with radical hysterectomy and pelvic lymphadenectomy. Of the 163 patients, 116 had preoperative serum CA125 levels, and 14 had pelvic lymph node metastasis. The investigation group comprised 102 lymph node-negative patients.
RESULTS: A cutoff value of 26 U/ml was obtained after the discriminant function analysis for identifying patients with positive lymph vascular space invasion (LVSI) or depth of stromal invasion > or =2/3 thickness. Multivariate analysis revealed that among the preoperative clinicopathological variables, including age, tumor size, parametrial invasion, and CA125 level, raised CA125 most significantly influenced the assessment of the LVSI (P = 0.040) and depth of cervical stromal invasion (P = 0.002).
CONCLUSIONS: In early-stage cervical adenocarcinoma with negative pelvic lymph node metastasis, preoperative serum CA125 levels at the cutoff value of 26 U/ml impacted the determination of the poor histopathological prognostic factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16290001     DOI: 10.1016/j.ygyno.2005.09.049

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  MicroRNA-335 represents an independent prognostic marker in cervical cancer.

Authors:  Changhe Wang; Tao Jiang
Journal:  Tumour Biol       Date:  2015-02-25

2.  Hepatoma-derived growth factor upregulation is correlated with prognostic factors of early-stage cervical adenocarcinoma.

Authors:  Ching-Chou Tsai; Shun-Chen Huang; Ming Hong Tai; Chan-Chao Chang Chien; Chao-Cheng Huang; Yi-Chiang Hsu
Journal:  Int J Mol Sci       Date:  2014-11-21       Impact factor: 5.923

3.  Combined Evaluation of Preoperative Serum CEA and CA125 as an Independent Prognostic Biomarker in Patients with Early-Stage Cervical Adenocarcinoma.

Authors:  Genping Huang; Ruizhe Chen; Nanjia Lu; Qin Chen; Weiguo Lv; Baohua Li
Journal:  Onco Targets Ther       Date:  2020-06-08       Impact factor: 4.147

4.  MicroRNA-466 with tumor markers for cervical cancer screening.

Authors:  Li-Li Zhou; Yong Shen; Jiao-Mei Gong; Ping Sun; Jia-He Sheng
Journal:  Oncotarget       Date:  2017-08-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.